Progress in direct reprogramming of dopaminergic cell replacement therapy

被引：1

作者：

Zheng, Yuan Yuan ^{[1
]}

Xu, Hui ^{[2
]}

Wang, Yue Si ^{[1
,3
,4
]}

机构：

[1] Binzhou Med Univ, Sch Pharm, Yantai 264003, Shandong, Peoples R China

[2] Binzhou Med Univ, Human Resources Dept, Yantai 264003, Shandong, Peoples R China

[3] Binzhou Med Univ, Med & Pharm Res Ctr, Yantai 264003, Shandong, Peoples R China

[4] Binzhou Med Univ, Yantai Key Lab Stem Cell & Regenerat Med, Yantai 264003, Shandong, Peoples R China

来源：

NEUROLOGICAL SCIENCES | 2024年 / 45卷 / 03期

关键词：

Parkinson's disease; Cell reprogramming; Induced dopamine neurons; Induced pluripotent stem cells; Induced neural stem cells; ADULT HUMAN FIBROBLASTS; PLURIPOTENT STEM-CELLS; PARKINSONS-DISEASE; NEURON CONVERSION; SOMATIC-CELLS; IN-VITRO; MOUSE; INDUCTION;

D O I：

10.1007/s10072-023-07175-z

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Parkinson's disease (PD) is a gradual neurodegenerative disease. While drug therapy and surgical treatments have been the primary means of addressing PD, they do not offer a cure, and the risks associated with surgical treatment are high. Recent advances in cell reprogramming have given rise to new prospects for the treatment of Parkinson's disease (PD), with induced pluripotent stem cells (iPSCs), induced dopamine neurons (iDNs), and induced neural stem cells (iNSCs) being created. These cells can potentially be used in the treatment of Parkinson's disease. On the other hand, this article emphasizes the limits of iPSCs and iNSCs in the context of Parkinson's disease treatment, as well as approaches for direct reprogramming of somatic cells into iDNs. The paper will examine the benefits and drawbacks of directly converting somatic cells into iDNs.

引用

页码：873 / 881

页数：9

共 50 条

[31] Current techniques in reprogramming cell potency
Romli, Firdaus
Alitheen, Noorjahan Banu
Hamid, Muhajir
Ismail, Ruzila
Abd Rahman, Nik-Mohd-Afizan Nik
JOURNAL OF CELLULAR BIOCHEMISTRY, 2013, 114 (06) : 1230 - 1237
[32] Kinetics of reprogramming in cell fusion hybrids
Choi, Hyun-Woo
Do, Jeong-Tae
INTERNATIONAL JOURNAL OF DEVELOPMENTAL BIOLOGY, 2010, 54 (11-12) : 1697 - 1702
[33] Cellular Programming and Reprogramming: Sculpting Cell Fate for the Production of Dopamine Neurons for Cell Therapy
Aguila, Julio C.
Hedlund, Eva
Sanchez-Pernaute, Rosario
STEM CELLS INTERNATIONAL, 2012, 2012
[34] Brain Repair by Cell Replacement via In Situ Neuronal Reprogramming
Qian, Hao
Fu, Xiang-Dong
ANNUAL REVIEW OF GENETICS, VOL 55, 2021, 55 : 45 - 69
[35] Disease Modeling of Neurodegenerative Disorders Using Direct Neural Reprogramming
Legault, Emilie M.
Bouquety, Julie
Drouin-Ouellet, Janelle
CELLULAR REPROGRAMMING, 2022, 24 (05) : 228 - 251
[36] Direct cell reprogramming is a stochastic process amenable to acceleration
Hanna, Jacob
Saha, Krishanu
Pando, Bernardo
van Zon, Jeroen
Lengner, Christopher J.
Creyghton, Menno P.
van Oudenaarden, Alexander
Jaenisch, Rudolf
NATURE, 2009, 462 (7273) : 595 - U63
[37] Small Molecules for Cell Reprogramming and Heart Repair: Progress and Perspective
Xie, Min
Cao, Nan
Ding, Sheng
ACS CHEMICAL BIOLOGY, 2014, 9 (01) : 34 - 44
[38] A review of induced pluripotent stem cell, direct conversion by trans-differentiation, direct reprogramming and oligodendrocyte differentiation
Prasad, Ankshita
Manivannan, Janani
Loong, Daniel T. B.
Chua, Soo M.
Gharibani, Payam M.
All, Angelo H.
REGENERATIVE MEDICINE, 2016, 11 (02) : 181 - 191
[39] Cell Reprogramming Techniques: Contributions to Cancer Therapy
Guo, Tongtong
Wei, Qi
CELLULAR REPROGRAMMING, 2023, 25 (04) : 142 - 153
[40] Are PARKIN patients ideal candidates for dopaminergic cell replacement therapies?
Kunath, Tilo
Natalwala, Ammar
Chan, Claire
Chen, Yixi
Stecher, Benjamin
Taylor, Martin
Khan, Sadaquate
Muqit, Miratul M. K.
EUROPEAN JOURNAL OF NEUROSCIENCE, 2019, 49 (04) : 453 - 462

← 1 2 3 4 5 →